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ABSTRACT In order to compile an inventory of national data sources for drug utilization 
research (DUR) in Argentina and to verify publicly available data sources, we performed 
a cross-sectional study that sought to identify national and provincial databases of drug 
use. In July 2020, we searched the websites of government institutions, carried out a 
systematic query of bibliographic databases for “drug utilization research” conducted in 
Argentina, and conducted a survey with local experts. Data collected included: the insti-
tution responsible for the database, population covered, accessibility, source of the data, 
healthcare setting, geographic information, and whether data were individual or aggrega-
ted. Descriptive analyses were then performed. We identified 31 data sources for DUR; 
only one was publicly and conveniently accessible. Five published aggregated data and 
provide more detailed access by formal request. Only seven sources (23%) reported natio-
nal data, and most (n=29) included only data from the public healthcare sector. Although 
data sources for DUR have been found in Argentina, limited access by researchers and 
policymakers is still an significant obstacle. Increasing health data transparency by making 
data sources publicly available for the purpose of analyzing public health information is 
crucial for building a stronger health system.
KEY WORDS Drug Utilization Evaluation; Pharmacoepidemiology; Drug Databases; 
Argentina.
RESUMEN Para realizar un inventario de fuentes de datos nacionales sobre utilización 
de medicamentos en Argentina y verificar las fuentes de datos disponibles públicamente, 
llevamos a cabo un estudio transversal que investiga la existencia de bases de datos 
nacionales y provinciales sobre utilización de medicamentos. En julio de 2020, realizamos 
una búsqueda en sitios web de instituciones gubernamentales, una búsqueda sistemática 
en bases de datos bibliográficas sobre “drug utilization research” en Argentina y una 
encuesta de expertos. Se identificaron 31 fuentes de datos de utilización de medicamentos, 
solo una era de acceso público y conveniente, cinco publicaban datos agregados y 
proporcionaban un acceso más detallado mediante solicitud formal, solo siete fuentes 
(23%) informaban datos nacionales, y la mayoría de ellas (n=29) incluían solo datos del 
sector pública de salud. Aunque se han encontrado fuentes de datos de utilización de 
medicamentos en Argentina, el acceso a investigadores y legisladores sigue siendo una 
barrera importante. Aumentar la transparencia de los datos de salud a través de fuentes 
disponibles públicamente para analizar la información de salud pública es crucial para 
construir un sistema de salud más sólido. 
PALABRAS CLAVES Evaluación de Utilización de Medicamentos; Farmacoepidemiolo-
gía; Bases de Datos Farmacéuticas; Argentina. 
































The need for data-driven decisions and re-
search-based knowledge to plan and imple-
ment health policies is essential. Although 
health data is generated and compiled con-
sistently, its evaluation is limited.
Drug Utilization Research (DUR) has 
been defined by the World Health Organiza-
tion (WHO) as “the marketing, distribution, 
prescription and use of drugs by society to de-
termine the resulting medical, social and eco-
nomic consequences,”(1) and more recently, 
as an “eclectic collection of descriptive and 
analytical methods for the quantification, 
the understanding and the evaluation of the 
processes of prescribing, dispensing and con-
sumption of medicines, and for the testing of 
interventions to enhance the quality of these 
processes.”(2) 
DUR is important to identify potential 
problems associated with drug use and to 
quantify them, as well as to design and eval-
uate drug policies. It may allow the identi-
fication and quantification of the divergence 
between data from clinical trials in experi-
mental conditions, daily clinical practice, and 
the health needs of the population, which 
are consolidated to design and implement 
best prescribing and dispensing practices. It 
is also useful to explore differences in drug 
exposure relative to specific outcomes and to 
optimize policies for promoting appropriate 
drug use.
Argentina has 45 million inhabitants and 
its health system consists of three subsectors: 
57% of people have health coverage through 
the “social security” subsector, which is a 
system of mandatory insurance linked to 
employment sector; 5% is covered through 
voluntary private insurance; and the remain-
ing 38% relies upon the public subsector.
(3) Due to its size, Argentina ranks fourth in 
Latin American pharmaceutical markets, with 
nearly 65% of drugs currently being supplied 
by locally-manufactured industries.(4)
As Argentina has a federal system of gov-
ernment, each of the 23 provinces and the 
Autonomous City of Buenos Aires has its own 
healthcare system. The national Ministry of 
Health fulfills regulatory and stewardship 
functions. National drug regulations cover 
everything from research to aspects related 
to the access, quality, and rational use of 
medicines. The national regulatory agency 
is known as the Administración Nacional 
de Medicamentos, Alimentos y Tecnología 
Médica (ANMAT), and it is considered a re-
gional reference regulatory agency by the Pan 
American Health Organization (PAHO).(5)
Concerning the use and access to med-
icines, the fragmentation of the healthcare 
system and the existence of different lists of 
essential medicines for each subsector im-
plies many challenges to providing equitable 
access to medicines. The Remediar Program 
is a program implemented in the public sub-
sector of the health system aimed at provid-
ing free access to essential medicines for 15 
million people, which has a positive redis-
tributive impact.(6) Argentina has also taken 
measures to encourage the rational use of 
drugs, such as the definition of a list of es-
sential drugs for the public subsector, the 
promotion of prescription and dispensing of 
generic drugs, and the development of guide-
lines for managing diseases covered by the 
social security subsector. Compliance with 
these regulations, however, is insufficient in 
the healthcare sector. 
In 1992, during the foundational meeting 
of the Argentine Group for the Rational Use 
of Medicines (Grupo Argentino para el Uso 
Racional de Medicamentos, or GAPURMED, 
for its Spanish acronym), the need to carry 
out pharmacoepidemiological studies was 
highlighted.(7) Since then, the group has 
produced countless field studies that have 
been presented at national meetings, many 
of them aimed at sensitizing involved health 
professionals, planning interventions to solve 
problems, and evaluating their impact. Un-
fortunately, most of these studies were not 
published nor did they become part of the 
gray literature, with little access to them. 
Over the years, only a small percentage of 
these studies have been published, mainly by 
universities or national journals. A few stud-
ies have been carried out using data sources 
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from institutions that provide medicines with 
coverage at the national or provincial level. 
Access to standardized and validated in-
formation on drug use is essential for evaluat-
ing drug use patterns, problem identification, 
educational interventions, and monitoring the 
results of access and rational use programs. 
DUR is important for policy formulation at 
the national level, as well as for individual 
patient management. But in Argentina, as 
in most Latin American countries, the avail-
ability of information on drug consumption 
and spending is scarce.(8) Furthermore, it 
is expected that at least the information on 
drug utilization from public entities be freely 
available, with the appropriate safeguards, to 
carry out DUR.
Therefore, this study aimed to identify data 
sources on drug use from public agencies and 
to verify their accessibility for DUR in Argen-
tina. This study is part of the ongoing “Data 
Sources for Drug Utilization Research in Latin 
American Countries: Cross-National Compar-
ison” (DASDUR-LATAM) Study,(9) which in-
tends to take an inventory of available national 
drug utilization data in the Latin American re-
gion as potential data sources for DUR.
METHODS
Design
This is a cross-sectional study that investi-
gates the existence of national and provincial 
data sources on drug utilization.
Search Strategy 
We combed through the websites of national 
and provincial government authorities that 
implement programs involving the use of 
medications, as well as those that provide in-
formation from the pharmaceutical industry, 
through July of 2020.
We searched bibliographic databases 
(Medline/PubMed and LILACS) for studies or 
documents published from the inception of 
the database up to and including July 2020, 
with no limits regarding publication date, 
publication type, or status. We also looked 
for examples of DUR that have been con-
ducted in Argentina or that involve the use of 
Argentinean data sources. 
The search strategy was based on thesau-
rus terms and free-text keywords to combine 
the concepts DUR and Argentina. Addition-
ally, we did a free-text search in Google 
Scholar and Google using the following key-
words both in English and in Spanish: drug 
use, drug utilization, DUR, Argentina, phar-
macoepidemiology, and database.
We conducted a brief online survey to 
complement information about the character-
ization of data sources, and to investigate the 
availability of databases at the provincial level 
(not accessible through their websites or from 
the bibliographic search). The survey was 
administered to the members of three drug 
networks: the aforementioned GAPURMED, 
the Argentine Network of Drug Information 
Centers (RACIM), and a national network 
of experts in health technology assessment. 
The questionnaire asked them about their 
knowledge and/or use of publicly accessi-
ble databases suitable for conducting DUR. 
If necessary, affirmative responses were con-
firmed via e-mail exchange with respondents. 
Type of data sources (eligibility criteria) 
We defined a data source for DUR as any 
data source with information about the use 
of medications including volume and price 
supported by governmental organizations.
We included public data sources at the 
national or provincial level, and/or data 
sources containing a mix of data from the 
public and private sectors. We excluded data 
from private organizations, individual hospi-
tals, or individual primary care or specialized 
clinics, and data sources from health insur-
ance companies or sickness funds. We also 
excluded data sources from commercial data 
providers, such as IQVIA. 
































Two researchers (MC and MAU) independently 
assessed data sources to decide whether they 
met the eligibility criteria. Possible divergences 
were resolved by a third researcher (GHM).
Data extraction and analysis
Once eligible data sources were identified, 
a checklist was used to extract the follow-
ing information: 1) institution responsible 
for the database; 2) covered population; 3) 
accessibility (publicly and convenient; re-
stricted pre-authorized protocol only access; 
available only to researchers working in the 
institution; unclear process for obtaining 
data, lack of general regulation; and other); 
4) source of the data (wholesalers, pharmacy, 
physician, others); 5) healthcare setting (hos-
pital, ambulatory care, both); 6) geographic 
scale (national, regional, provincial, other); 7) 
type of data (aggregated or individual level). 
Data were analyzed descriptively.
RESULTS
A total of 35 publicly available data sources 
were identified. Seven databases derived from 
official websites on drug use, 10 data sources 
found through bibliographic searches, and an 
additional 18 data sources at the provincial 
level identified through the online survey that 
included responses from 30 drug experts. 
Once the duplicated data sources were 
excluded, 31 different sources of information 
for DUR remained: seven (23%) reported na-
tional data and the other 24 provincial-level 
data (Figure 1). 
Our query of the Argentine Ministry of 
Health’s website identified the Argentine In-
tegrated Health Information System (SISA, for 
Sistema Integrado de Información Sanitaria 
Argentino), which was developed to serve as 
the basis for harmonizing data from different 
registries and programs with national reach, 
seeking to articulate pre-existing information 
sources in an integrated framework.(10) Some 
of the national drug data sources identified 
were already included in SISA (Remediar 
Program and SUMAR). The other two were 
INDEC and PAMI (Table 1). 
The Remediar Program is a national gov-
ernment program that provides free access 
to essential medications to the population 
covered exclusively by the public sector 
and is implemented through the provincial 
health services. The program has been used 
to perform several DUR.(11,12,13,14,15) Data 
generated by the program are obtained from 
the prescription forms that include patient 
data (name, age, sex, etc.), coded diagnosis, 
and drug name. The program has a comple-
mentary data source called “transferencias 
monetarias por medicamentos” (cash trans-
fers for medications) that offers an overview 
of transfers (drug, number of packages by 
province, ATC code in the first level, and 
year) made by the Remediar Program. Infor-
mation can be visualized at the national and 
provincial levels.
SUMAR is a national program that pro-
vides basic effective coverage for people 
without other forms of health insurance. 
Although common ambulatory drugs are 
provided through the Remediar Program, 
treatment for specific diseases and high-cost 
medicines might be supplied by SUMAR. 
Data from SUMAR contains information 
about beneficiaries, services, benefits, and 
medications provided by the program. Ac-
cess to data is available only to researchers 
working in the institution.(16)
INDEC is the Instituto Nacional de Es-
tadística y Censos (National Institute of Sta-
tistics and Census). The Institute provides 
quarterly data on sales revenues of pharma-
ceutical products for human use, classified 
by the first level of the Anatomical Therapeu-
tic Classification (ATC) of the World Health 
Organization, and provides information on 
production at the national level, resale of im-
ports, country of origin of basic drugs, among 
other data. Furthermore, INDEC conducts pe-
riodic surveys of household consumption and 
surveys of risk factors for chronic diseases in 
the general population, in cooperation with 
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the National Ministry of Health. These sur-
veys have been used to report specific as-
pects of drug use, such as the family spending 
on drugs, or the prevalence of drug use for 
diabetes or hypertension.(17,18)
PAMI is the National Institute of Social 
Services for Retirees and Pensioners, provid-
ing medical assistance to 76% of people in 
the country over 65 years of age.(19) The data-
base contains individualized information on 
outpatient drug dispensations, including ge-
neric and brand name, pharmaceutical prod-
uct, total price, and out-of-pocket expense. 
This database has been used for studies of 
psychotropic and hypertension drugs, among 
others.(18,20,21,22)
The other three national data sources fo-
cused on specific issues. They are: the Na-
tional Pharmacovigilance System (SNFV, for 
its Spanish acronym); the National Program 
for HIV Care; and the National Bank of Spe-
cial Drugs, dedicated mainly to the provision 
of cancer drugs.
The National Pharmacovigilance System – 
operating within the ANMAT – is in charge of 
detecting, evaluating, understanding, and pre-
venting adverse effects derived from the use 
of medications and vaccines. The database of 
the Pharmacovigilance Department contains 
the necessary information for monitoring and 
control actions. In addition to annual reports, 
some DUR has been published.(23,24) 
The Drug Bank at the National Ministry 
of Health provides essential cancer drugs to 
patients who only have public health cover-
age and receive care in public hospitals.(25) 
Similarly, the National Program for the Pre-
vention and Control of HIV/AIDS provides 
antiretroviral drugs to the same population. 
Aggregated reports of the Program are regu-
larly updated.(26,27)
The coverage of uninsured people by the 
public sector is provided by 24 provincial 
healthcare systems; outpatient medications 
are supplied by the Remediar Program, which 
is described above. In addition, the provinces 
have their own social security systems (Obra 
Social Provincial, or OSP) for public employ-
ees and their families. Therefore, there are 24 
OSPs, each one with its own administrative 
Potential data sources identied 
through website search from 
government institutions
 (n=7)
Data sources screened 
(n=35)
Data sources included for 
qualitative analysis 
(n=31)
Adittional data sources found 
by a survey of drug 
experts (n=18)
Data sources found by systematic 
search for drug utilization research  




Figure 1. Data sources mapping flow diagram for drug utilization data sources, Argentina, July 2020.
Source: Own elaboration from Medline-PubMed, Literatura Latinoamericana y del Caribe en Ciencias de la Salud (LILACS) and Google Scholar data.
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CSS Caja de Servicios Sociales
Restricted access to program 
managers, (however some 
limited data could be 
available). Online data sources 
no available
Provincial Individual level data
Ministry of 
Health, Province 
of Santa Cruz 
Website Public Pharmacy records
Ambulatory 
only Unknown
DOS Dirección de Obra Social
Restricted access to program 
managers, (however some 
limited data could be 
available). Online data sources 
no available
Provincial Individual level data
Ministry of 
Health, Province 
of San Juan 




Dirección de Obra 
Social del Estado 
Provincial
Restricted access to program 
managers, (however some 
limited data could be 
available). Online data sources 
no available












Restricted access to program 
managers, (however some 
limited data could be 
available). Online data sources 
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Social Seguros y 
Préstamos
Restricted access to program 
managers, (however some 
limited data could be 
available). Online data sources 
no available











Restricted access to program 
managers, (however some 
limited data could be 
available). Online data sources 
no available











Obra Social de 
Corrientes
Restricted access to program 
managers, (however some 
limited data could be 
available). Online data sources 
no available












Restricted access to program 
managers, (however some 
limited data could be 
available). Online data sources 
no available
Provincial Individual level data
Ministry of 
Health, Province 
of Santiago del 
Estero
Website Public Pharmacy records
Ambulatory 
only Unknown






























Obra Social de 
la provincia de 
Entre Ríos
Restricted access to program 
managers, (however some 
limited data could be 
available). Online data sources 
no available











Restricted access to program 
managers, (however some 
limited data could be 
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managers, (however some 
limited data could be 
available). Online data sources 
no available











Restricted access to program 
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Restricted access to program 
managers, (however some 
limited data could be 
available). Online data sources 
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Website Public Pharmacy records
Ambulatory 
only Unknown
ISJ Instituto de Seguros de Jujuy
Restricted access to program 
managers, (however some 
limited data could be 
available). Online data sources 
no available











Restricted access to program 
managers, (however some 
limited data could be 
available). Online data sources 
no available








Obra Social de 
la Ciudad de 
Buenos Aires
Restricted access to program 
managers, (however some 
limited data could be 
available). Online data sources 
no available
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Obra Social de 
la Provincia de 
Tierra del Fuego, 
Antártida e Islas 
del Atlántico Sur
Restricted access to program 
managers, (however some 
limited data could be 
available). Online data sources 
no available
Provincial Individual level data
Ministry of 
Health, Province 
of Tierra del 
Fuego







Restricted access to program 
managers, (however some 
limited data could be 
available). Online data sources 
no available








Obra Social de 
los Empleados 
Públicos
Restricted access to program 
managers, (however some 
limited data could be 
available). Online data sources 
no available
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accessible online. Detailed 
data available to institution 
researchers or by special 
request. PAMI also has a data 
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data, which would be a potential data source 
for DUR. The IOMA, the Province of Buenos 
Aires’ OSP – which covers about 2,000,000 
people – is presented as case in point. It has 
an administrative database that contains in-
formation about dispensed medications, but 
access is limited to internal users. A small 
number of studies using this data have been 
published.(28,29)
Only INDEC and National Pharmacovig-
ilance System data include information about 
both the public and private sectors; all other 
sources cover public institutions.
In terms of the accessibility of data sources, 
INDEC data are publicly and conveniently ac-
cessible online. SUMAR, the Remediar Pro-
gram, PAMI, the National Pharmacovigilance 
System, and the HIV/AIDS Program regularly 
publish aggregated data on their websites. 
Studies that go into greater detail are available 
only to researchers working in the institution, 
or via formal requests for research purposes. 
This is also the case of the 24 OSPs. PAMI 
and the National Pharmacovigilance System 
have data request forms on their websites. The 
other data sources lack a clear process for ob-
taining data. 
The INDEC database provides wholesaler 
information while the Remediar Program of-
fers information on wholesale transfers from 
the program to the Provinces, patient record 
data, and individual dispensation data. The 
SUMAR database contains patient records and 































Website Public Wholesalers Ambulatory only
Available 
since 2003
SEMPRE Servicios Médicos Previsional
Restricted Access to Program 
Managers, (however some 
limited data could be 
available). Online data sources 
no available
Provincial Individual level data
Ministry of 
Health, Province 
of La Pampa 





Seguridad Social y 
Seguros-Servicio 
de Obra Social
Restricted Access to Program 
Managers, (however some 
limited data could be 
available). Online data sources 
no available




Website Public Pharmacy records
Ambulatory 
only Unknown
SNFV Sistema Nacional de Farmacovigilancia
Publicly and conveniently 
accessible on line. Detailed 
data available to institution 
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provide individual dispensation information 
through pharmacy records, except for the Na-
tional Pharmacovigilance System, which reg-
isters individual adverse effects reports. The 
data from SUMAR, the Remediar Program, 
PAMI, the HIV/AIDS Program, and the 24 
OSPs refer to outpatient settings. INDEC, the 
Drug Bank for cancer medicines and the Na-
tional Pharmacovigilance System contain both 
outpatient and inpatient data, although only 
the last allows us to separate them.
Regarding geographic information, na-
tional data from SUMAR, the Remediar Pro-
gram, PAMI, National Pharmacovigilance 
System, and the HIV/AIDS Program are dis-
aggregated at the Province level. 
DISCUSSION 
There are multiple data sources for DUR in 
Argentina, at both the national and provincial 
levels. However, the lack of public availabil-
ity and accessibility for DUR are important 
barriers for researchers and policymakers. 
Few data sources offered access to data 
through the website (Table 1). The authors 
of most published studies that we reviewed 
belonged to the institution in which the study 
was carried out.(11,29)
Our study only considered data sources 
from the public sector, but excluded those 
that provide healthcare coverage for em-
ployees of national universities, the Armed 
Forces, and the Judiciary and Legislative sys-
tems, due to their restricted scope. Nonethe-
less, the set of national and provincial data 
sources identified are responsible for cover-
ing more than 60% of the country’s popu-
lation. The rest of the population is covered 
by autonomous health insurance institutions 
in the social security subsector – which are 
regulated by the Superintendence of Health 
Services – and private insurance providers.(30)
A recent study that evaluated data sources 
for conducting “real-world evidence” research 
identified 44 data sources in Argentina. This 
study was driven by the possibility of carry-
ing out health technology assessment studies 
in the broadest sense, which far exceeds the 
objective of our study, which was limited to 
DUR. However, the details of all analyzed da-
tabases were not provided, so it is not possi-
ble to establish direct comparisons.(31)
The value of clinical information stored 
in electronic medical records and adminis-
trative databases has been well established 
for a long time. As early as the late 1980s, 
the first primary care research databases were 
created in the United Kingdom; today there 
are numerous examples in many countries.(32) 
More recently, the metaphor of a “health 
ecosystem” has gained traction, to empha-
size the multiplicity of actors in the health-
care sector and the dynamic nature of their 
interactions.(33) Data transparency, defined as 
the open access to information generated by 
public institutions, would make a significant 
contribution to better understanding their op-
eration.(34)
Obstacles to DUR in Latin American 
countries have recently been pointed out, 
and include factors such as the fragmentation 
of health systems, the inexistence of data-
bases at the national level, and the lack of 
knowledge on the part of decision-makers re-
garding this type of study.(35)
Comparisons between Latin American 
countries have been poorly documented. 
Also, the validity of comparisons is hampered 
by the potential risk of extrapolation bias, 
considering the availability of data on the use 
of medications in the public health sector.(8)
Health systems, funders, and provid-
ers must permanently record data to cor-
rect, adapt, or control healthcare claims. In 
pharmacoepidemiology, drug databases are 
necessary to monitor the prescription, dis-
pensing, or consumption of drugs in a given 
population. However, the information gen-
erated by different actors in the healthcare 
system is reserved mainly for internal use in 
many countries and rarely shared with other 
institutions in the network.
As a result, even when drug databases 
are becoming more and more numerous, 
very few of them are freely and transparently 
accessible. Furthermore, many drug utiliza-
tion data sources were identified through a 































survey because they were not openly pub-
lished. Obtaining data from public entities 
is discretionary as explicit requirements for 
accessing data are not stated.
Another source of drug use data is pri-
vate companies, such as IQVIA, which col-
lect retail sales information. However, these 
data correspond to the consumption of drugs 
in the private sector, and should not be ex-
trapolated to the total national population. 
Thus, there is a growing need for re-
searchers and policymakers to work together 
to establish nationally validated data collec-
tion systems to accurately describe drug use 
in the country. Priority should be given to 
data from the public sector.
This study has shown that access to data 
sources for DUR from public entities in Argen-
tina is limited. Although there is legislation 
in effect that guarantees access to public in-
formation (Law 27275)(36) and requires public 
agencies to provide essential data to the pub-
lic regarding their activities, not all institutions 
have complied with these regulations. This 
situation is similar to other countries in the 
region.(37)
Increasing health data transparency by 
making data sources publicly available for 
the purpose of analyzing public health in-
formation is crucial for structuring a stronger 
healthcare system and making data-driven 
decisions.
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